Company news

Revolution Medicines, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

November 5, 2023

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

October 31, 2023

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

October 30, 2023

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

October 21, 2023

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

October 12, 2023

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

October 3, 2023

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

September 18, 2023

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

August 16, 2023

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

August 7, 2023

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

August 2, 2023

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

July 31, 2023

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

May 23, 2023

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

May 7, 2023

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

April 30, 2023

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

April 12, 2023

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

April 5, 2023

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

March 6, 2023

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

March 1, 2023

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

February 26, 2023

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

February 20, 2023

Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

December 18, 2022

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

December 6, 2022

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

November 6, 2022

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

October 31, 2022

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

September 21, 2022

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

August 31, 2022

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

August 8, 2022

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

July 27, 2022

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

July 21, 2022

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

July 18, 2022

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

July 12, 2022

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

June 27, 2022

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

June 8, 2022

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

May 8, 2022

Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

April 20, 2022

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

March 8, 2022

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

February 28, 2022

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

February 27, 2022

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

February 21, 2022

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

February 2, 2022

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 10, 2022

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

November 23, 2021

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

November 9, 2021

Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

November 7, 2021

Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021

November 2, 2021

Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

September 29, 2021

Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

September 14, 2021

Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.